Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AzurRx BioPharma, Inc. (OTC: AZRX).

Full DD Report for AZRX

Recent News from (OTC: AZRX)

NetworkNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Releases Positive AZX1103 Preclinical Results
AzurRx BioPharma Inc. (NASDAQ: AZRX) today released positive results for preclinical testing of its AZX1103 product, a b-lactamase enzyme combination treatment designed to prevent hospital-acquired gastro-intestinal infections for patients receiving antibiotics in the hospital setting. As stat...
Source: NetworkNewsWire
Date: April, 18 2018 09:30
AzurRx BioPharma Announces Positive Preclinical Data with AZX1103
Company is developing AZX1103 for the prevention of nosocomial infections induced by administration of several classes of antibiotics AZX1103 shown to be safe and biologically active in a well-established pre-clinical model  BROOKLYN, N.Y., April 18, 2018 (GLOBE NEWSWIRE) -- AzurR...
Source: GlobeNewswire
Date: April, 18 2018 07:45
Stock Market Manager Announces the Hosting of Research Coverage of AzurRx, Biopharma, Inc. (NASDAQ: AZRX) by Trickle Research LLC
CLEARWATER, FL / ACCESSWIRE / March 2, 2018 / The AzurRx Biopharma, Inc. (NASDAQ: AZRX) research report is available on Stock Market Manager ( smm.global ): Research Report Here>> About AzurRx, Biopharma, Inc. AzurRx BioPharma is a development stage biopharmaceutical c...
Source: ACCESSWIRE IA
Date: March, 02 2018 09:00
AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)
BROOKLYN, N.Y., Feb. 28, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be...
Source: GlobeNewswire
Date: February, 28 2018 08:30
AzurRX Biopharma (AZRX) Presents At BIO CEO & Investor Conference - Slideshow
The following slide deck was published by AzurRX Biopharma in conjunction with this Read more ...
Source: SeekingAlpha
Date: February, 13 2018 13:58
NetworkNewsBreaks - AzurRx BioPharma, Inc. (NASDAQ: AZRX) Adds Three New Patients to Phase IIA Study of MS1819-SD
AzurRx BioPharma, Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, this morning announced that, in partnership with French pharmaceutical firm Mayoly Spindler, it has enrolled three new patients to its phase II...
Source: NetworkNewsWire
Date: February, 12 2018 09:30
AzurRx BioPharma Announces Enrollment of Three New Patients for its Phase IIa Study of MS1819-SD
BROOKLYN, N.Y., Feb. 12, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today that in partnership...
Source: GlobeNewswire
Date: February, 12 2018 08:15
AzurRx BioPharma to Present at the 2018 BIO CEO & Investor Conference (February 12th)
BROOKLYN, N.Y., Feb. 08, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, announced today the Company will be...
Source: GlobeNewswire
Date: February, 08 2018 16:30
AzurRx BioPharma up 13%
Thinly traded nano cap AzurRx BioPharma ( AZRX +13.4% ) perks up on almost a 4x surge in volume, albeit on turnover of only 171K shares. More news on: AzurRX Biopharma, Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: January, 30 2018 13:54
SeeThruEquity Initiates Coverage on AzurRx BioPharma, Inc. (NASDAQ CM: AZRX) with a Price Target of $10.00
NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has initiated coverage on AzurRx BioPharma, Inc. (NASDAQ: AZRX) with a 12-month price target o...
Source: ACCESSWIRE IA
Date: January, 30 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-223.693.443.69083.4411,714
2018-04-213.693.443.69083.4411,714
2018-04-203.693.443.69083.4411,714
2018-04-193.513.523.60073.3912,143
2018-04-183.653.583.74413.18124,780

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

Short Analysis provided by Squeeze Report.


About AzurRx BioPharma, Inc. (OTC: AZRX)

Logo for AzurRx BioPharma, Inc. (OTC: AZRX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (OTC: AZRX)

      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 16 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: February, 13 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 13 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 13 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 13 2018
      Annual statement of changes in beneficial ownership of securities
      Filing Type: 5Filing Source: edgar
      Filing Date: February, 13 2018
      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: January, 19 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: January, 08 2018

       

       


      Daily Technical Chart for (OTC: AZRX)

      Daily Technical Chart for (OTC: AZRX)


      Stay tuned for daily updates and more on (OTC: AZRX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (OTC: AZRX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AZRX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of AZRX and does not buy, sell, or trade any shares of AZRX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

       

       

      Release this Report to Investors

      Via Email

      Via Text

      Important

      If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us